Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case report and literature review

Quick complete response achievement with venetoclax and azacitidine in a case of relapsed disseminated blastic plasmacytoid dendritic cell neoplasm

(2020) Matteo Piccini et al.   ANNALS OF HEMATOLOGY

Blastic plasmacytoid dendritic cell neoplasm

(2020) Kendra Sweet   CURRENT OPINION IN HEMATOLOGY

Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm

(2019) Naveen Pemmaraju et al.   NEW ENGLAND JOURNAL OF MEDICINE

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics and Outcomes in the Rapidly Evolving Modern Targeted Therapy Era

(2019) Naveen Pemmaraju et al.   BLOOD

DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance

(2019) Katsuhiro Togami et al.   JOURNAL OF CLINICAL INVESTIGATION

Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target

(2018) Maria Rosaria Sapienza et al.   HAEMATOLOGICA

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax

(2016) Joan Montero et al.   Cancer Discovery

Treatment of blastic plasmacytoid dendritic cell neoplasm

(2016) J. M. Sullivan et al.   Hematology-American Society of Hematology Education Program

Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: focus on biallelic locus 9p21.3 deletion

(2011) M. Lucioni et al.   BLOOD